Skip to content

Depreciation at other companies

Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$106.5M+159%
Operating income$72.6M+349%
Net income$40.8M+209%
EPS (diluted)$0.24+204%

Balance sheet

See full
Cash & equivalents$220.5M+103%
Total debt$212.4M+1,323%
Total equity-$217.1M+35.0%
Total assets$434.6M+32.8%

Cash flow

See full
Operating cash flow$5.1M-74.3%
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$632.12M+457%
Enterprise value$624M+3,024%
P/E6.2×
P/S1.8×+1.4×

Profitability

See full
Gross margin99.2%
Operating margin55.4%+38.7pp
Net margin28.3%+22.3pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio1.4×-1.9×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ironwood Pharmaceuticals's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ironwood Pharmaceuticals's depreciation?
Ironwood Pharmaceuticals (IRWD) reported depreciation of $443K in Q1 2026.
How has Ironwood Pharmaceuticals's depreciation changed year-over-year?
Ironwood Pharmaceuticals's depreciation decreased by 7.5% year-over-year, from $479K to $443K.
What is the long-term trend for Ironwood Pharmaceuticals's depreciation?
Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's depreciation has grown at a 5.4% compound annual growth rate (CAGR), from $1.52M to $1.88M.